Alseres (US-Massachusetts) Drug Class: Small molecule and Peptide Mechanism/Technology: Cethrin: compound which inhibits the Rho signaling pathway contributing to axon regeneration and functional recovery of movement and sensation following spinal cord injury-currently in Phase II trials. Inosine and Oncomodulin: currently in preclinical development for TBI, SCI, and stroke, Nogo inhibitors in preclinical development for SCI Primary Indication: Spinal cord injury, traumatic brain injury, stroke Stage: Phase II
